Valuation: Evotec SE

Market Cap 583M 681M 546M 499M 942M 65.18B 952M 6.46B 2.51B 32.73B 2.56B 2.5B 108B P/E 2026 *
-2.79x
P/E 2027 * -7.61x
Enterprise Value 726M 847M 679M 621M 1.17B 81.14B 1.18B 8.04B 3.13B 40.74B 3.18B 3.11B 135B EV / Sales 2026 *
1.21x
EV / Sales 2027 * 1.04x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
1 day-0.93%
1 week-3.67%
Current month-3.44%
1 month-3.89%
3 months-35.79%
6 months-42.95%
Current year-39.38%
1 week 3.25
Extreme 3.254
3.47
1 month 3.25
Extreme 3.254
3.82
Current year 3.24
Extreme 3.238
6.66
1 year 3.24
Extreme 3.238
7.49
3 years 3.24
Extreme 3.238
23.25
5 years 3.24
Extreme 3.238
45.7
10 years 3.24
Extreme 3.238
45.7
Manager TitleAgeSince
Chief Executive Officer 55 2024-06-30
Director of Finance/CFO - 2026-04-30
Chief Operating Officer - 2026-04-30
Director TitleAgeSince
Director/Board Member 58 2019-06-18
Director/Board Member 64 2021-05-31
Director/Board Member 59 2024-06-09
Change 5-day change 1-year change 3-year change Capi.($)
-0.48%-3.67% - - 696M
-0.74%+4.48%+3.74%+22.46% 51.61B
+1.01%-0.19%+493.19%+564.96% 44.89B
+0.16%+7.83%+38.35%+20.70% 42.77B
-0.66%+2.62%+20.54%+87.06% 42.58B
+0.88%-3.48%+17.20%+57.20% 31.82B
-0.12%+3.82%+32.81%+145.21% 17.33B
-0.53%+1.61% - - 16.63B
+0.58%+4.00%+7.17%+30.59% 14.76B
+1.15%+4.10%+81.83%+50.24% 14.09B
Average +0.00%+4.83%+86.85%+122.30% 30.72B
Weighted average by Cap. -0.01%+5.13%+104.77%+140.89%

Financials

2026 *2027 *
Net sales 600M 700M 561M 513M 968M 67B 978M 6.64B 2.58B 33.64B 2.63B 2.57B 111B 719M 839M 673M 615M 1.16B 80.36B 1.17B 7.96B 3.1B 40.35B 3.15B 3.08B 134B
Net income -236M -275M -221M -202M -381M -26.35B -385M -2.61B -1.02B -13.23B -1.03B -1.01B -43.78B -60.37M -70.45M -56.48M -51.63M -97.44M -6.75B -98.48M -668M -260M -3.39B -265M -259M -11.21B
Net Debt 143M 167M 134M 122M 231M 15.96B 233M 1.58B 615M 8.01B 626M 612M 26.52B 162M 189M 152M 139M 262M 18.12B 265M 1.8B 698M 9.1B 710M 695M 30.1B
Logo Evotec SE
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
4,461
Date Price Change Volume
26-08-24 3.310 -0.48% 1,000
26-08-21 €3.326 -2.18% 0
26-08-20 €3.400 -1.39% 8,451
26-08-19 €3.448 +1.23% 5,710
26-08-18 €3.406 +0.29% 5,250
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
3.356EUR
Average target price
4.586EUR
Spread / Average Target
+36.64%

Quarterly revenue - Rate of surprise